PET scan 18F-fluorodeoxyglucose uptake and prognosis in patients with resected clinical stage IA non-small cell lung cancer

Chest

Volumn 137, Issue 5, 2010, Pages 1150-1156

  Nair, Viswam S ^a   Barnett, Paul G ^b,c   Ananth, Lakshmi ^c   Gould, Michael K ^a,b,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADJUVANT THERAPY; AGE DISTRIBUTION; AGED; ARTICLE; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER SURVIVOR; CLINICAL ASSESSMENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HAZARD RATIO; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; ADENOCARCINOMA; FOLLOW UP; KAPLAN MEIER METHOD; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 77951839766     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.09-2356     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71-96.
2. Mountain CF. A New International Staging System for Lung Cancer. Chest. 1986;89(4S):S225-S233.
3. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997;111(6):1710-1717. (Pubitemid 27260107)
4. Rami-Porta R, Ball D, Crowley J, et al; International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2007;2(7):593-602.
5. Naruke T, Goya T, Tsuchiya R, Suemasu K. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg. 1988;96(3):440-447.
6. Buccheri G, Ferrigno D. Prognostic value of stage grouping and TNM descriptors in lung cancer. Chest. 2000;117(5):1247-1255. (Pubitemid 30321575)
7. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350(4):351-360.
8. Pignon JP, Tribodet H, Scagliotti GV, et al; LACE Collaborative Group. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552-3559.
9. Strauss GM, Herndon JE II, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008;26(31):5043-5051.
10. de Geus-Oei LF, van Krieken JH, Aliredjo RP, et al. Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer. 2007;55(1):79-87. (Pubitemid 46038871)
11. Higashi K, Ueda Y, Yagishita M, et al. FDG PET measurement of the proliferative potential of non-small cell lung cancer. J Nucl Med. 2000;41(1):85-92. (Pubitemid 30046688)
12. Berghmans T, Dusart M, Paesmans M, et al; European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in nonsmall cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol. 2008;3(1):6-12.
13. de Geus-Oei LF, van der Heijden HF, Corstens FH, Oyen WJ. Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. Cancer. 2007;110(8):1654-1664.
14. 18F-FDG PET and CT in the characterization of solitary pulmonary nodules. J Nucl Med. 2008;49(2):179-185.
15. 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med. 2006;47(6):1059-1066.
16. Bland JM, Altman DG. The logrank test. BMJ. 2004;328(7447):1073.
17. Higashi K, Ueda Y, Arisaka Y, et al. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med. 2002;43(1):39-45. (Pubitemid 34101186)
18. Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg. 2005;130(1):151-159. (Pubitemid 40941684)
19. Ohtsuka T, Nomori H, Watanabe K, et al. Prognostic signifi cance of [(18)F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma. Cancer. 2006;107(10):2468-2473. (Pubitemid 44748531)
20. Downey RJ, Akhurst T, Gonen M, Park B, Rusch V. Fluorine-18 fluorodeoxyglucose positron emission tomographic maximal standardized uptake value predicts survival independent of clinical but not pathologic TNM staging of resected non-small cell lung cancer. J Thorac Cardiovasc Surg. 2007;133(6):1419-1427.
21. Jeong HJ, Min JJ, Park JM, et al. Determination of the prognostic value of [(18)F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl Med Commun. 2002;23(9):865-870.
22. Hanin FX, Lonneux M, Cornet J, et al. Prognostic value of FDG uptake in early stage non-small cell lung cancer. Eur J Cardiothorac Surg. 2008;33(5):819-823.
23. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A. 2001;98(24):13790-13795. (Pubitemid 33115977)
24. Ou SH, Zell JA, Ziogas A, Anton-Culver H. Prognostic factors for survival of stage I nonsmall cell lung cancer patients : a population-based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003. Cancer. 2007;110(7):1532-1541.
25. Ost D, Goldberg J, Rolnitzky L, Rom WN. Survival after surgery in stage IA and IB non-small cell lung cancer. Am J Respir Crit Care Med. 2008;177(5):516-523. (Pubitemid 351442190)
26. Thie JA. Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med. 2004;45(9):1431-1434.
27. Lardinois D, Weder W, Hany TF, et al. Staging of non-smallcell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348(25):2500-2507. (Pubitemid 36706537)
28. Scagliotti GV, Fossati R, Torri V, et al; Adjuvant Lung Project Italy/European Organisation for Research Treatment of Cancer-Lung Cancer Cooperative Group Investigators. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst. 2003;95(19):1453-1461.
29. Waller D, Peake MD, Stephens RJ, et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg. 2004;26(1):173-182. (Pubitemid 38759943)
30. Winton T, Livingston R, Johnson D, et al; National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352(25):2589-2597.
31. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7(9):719-727. (Pubitemid 44283661)